SattarN, LeeMMY, KristensenSL, et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomized trials. Lancet Diabetes Endocrinol, 2021; 9(10):653–662; doi: 10.1016/S2213-8587(21)00203-5
2.
NewsomePN, BuchholtzK, CusiK, et al.NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021; 384(12):1113–1124; doi: 10.1056/NEJMoa2028395
3.
ZhengZ, ZongY, MaY, et al.Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct Target Ther, 2024; 9(1):234; doi: 10.1038/s41392-024-01931-z
4.
AdhikariR, JhaK, DardariZ, et al.National trends in use of Sodium-Glucose Cotransporter-2 inhibitors and glucagon-like Peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc, 2022; 11(9):e023811; doi: 10.1161/JAHA.121.023811
5.
YeoYH, RezaieA, HsiehTY, et al.Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group. Shifting trends in the indication of Glucagon-like Peptide-1 receptor agonist prescriptions: A nationwide analysis. Ann Intern Med, 2024; 177(9):1289–1291; doi: 10.7326/m24-0019
BezinJ, GouverneurA, PénichonM, et al.GLP-1 Receptor agonists and the risk of thyroid cancer. Diabetes Care, 2023; 46(2):384–390; doi: 10.2337/dc22-1148
10.
SilveriiGA, MonamiM, GalloM, et al.Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab, 2024; 26(3):891–900; doi: 10.1111/dom.15382
11.
PasternakB, WintzellV, HviidA, et al.Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian Cohort Study. BMJ, 2024; 385:e078225; doi: 10.1136/bmj-2023-078225
12.
AlvesC, Batel-MarquesF, MacedoAF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer. Diabetes Res Clin Pract, 2012; 98(2):271–284; doi: 10.1016/j.diabres.2012.09.008
13.
CaoC, YangS, ZhouZ. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials. Endocrine, 2019; 66(2):157–165; doi: 10.1007/s12020-019-02055-z
14.
HuW, SongR, ChengR, et al.Use of GLP-1 Receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne), 2022; 13:927859; doi: 10.3389/fendo.2022.927859
15.
BaxterSM, AndersenJH, BrixTH, et al.Glucagon-like Peptide 1 receptor agonists and risk of thyroid cancer: An International Multisite Cohort Study. Thyroid, 2024 In press.
16.
Berrington de GonzalezA, Iulian ApostoaeiA, VeigaLHS, et al.RadRAT: A radiation risk assessment tool for lifetime cancer risk projection. J Radiol Prot, 2012; 32(3):205–222; doi: 10.1088/0952-4746/32/3/205
